Physicians' Academy for Cardiovascular Education

Clinical trials in diabetes and CVD: What did we learn?

10' education - Mar. 22, 2018 - Filippo Crea, Angelyn Bethel, Eduard Montanya

What are the key mechanisms of CV benefit of novel diabetes drugs?

10' education - Mar. 22, 2018 - Lina Badimon, Jochen Seufert, Naveed Sattar

What is the science driving CVD and T2DM?

10' education - Mar. 22, 2018 - Wouter Jukema, Stephan Jacob, Ulf Landmesser

Key classes of antidiabetic drugs – How do they work?

10' education - Feb. 14, 2018 - Prof Cliff Bailey - Birmingham, UK

Diabetes cardiovascular outcome trials

10' education - Feb. 14, 2018 - Prof. Lawrence Leiter, MD - Toronto, ON, Canada

Diabetic patients with chronic kidney disease may benefit more from GLP-1 analogue treatment

10' education - Nov. 15, 2017

Diabetes therapies and CVD – Does the ‘how’ matter more than the how much?

10' education - Oct. 27, 2017 - Boston, MA, USA - Dr. Stephen Wiviott - Brigham & Women's Hospital, Boston, USA

New therapeutic options can make a difference for diabetic patients with high CV risk

3' education - Aug. 29, 2017 - Prof. John E Deanfield, MD - London, UK

Cardiovascular protection in type 2 diabetes

5' education - Aug. 29, 2017 - Prof. Lars Rydén, cardiologist, Stockholm, Sweden

Brief update on the LEADER cardiovascular outcomes trial

10' education - Oct. 15, 2017 - Prof. Neil Poulter, cardiologist, London, UK

Management of CV Risk & T2DM: Implications of novel outcome trials

10' education - Aug. 28, 2017 - Barcelona, Spain - John E Deanfield, MD, London, UK - PACE-CME symposium held at ESC 2017

SGLT2 inhibition in cardiology: What a cardiologist needs to know

10' education - Aug. 28, 2017 - Barcelona, Spain - Naveed Sattar, MD, Oxford, United Kingdom - PACE-CME symposium held at ESC 2017

How incretin therapy changes diabetes and prediabetes management

3' education - May 22, 2017

New diabetes drugs and heart failure: What have we learnt?

10' education - May 6, 2017 - Paris, France - John McMurray, MD - ESC Heart Failure, Paris

Modifying CV risk by managing diabetes

3' education - Nov. 12, 2016 - New Orleans, LA, USA - Jorge Plutzky, MD (Boston, MA, USA)
##SCROLLER_ITEMS_FULL_TITLE##

What do novel diabetes drugs add to CV risk reduction?

3' education - Oct. 19, 2014 - Snapshot 2014 - Dr Naveed Sattar
##SCROLLER_ITEMS_FULL_TITLE##

Effects of GLP-1 Analogs on Cardiovascular Health

3' education - Jan. 10, 2013 - LA, AHA 2012 - Dr. Richard Shannon

GLP-1 analog reduces major CV outcomes in patients with atherosclerotic poly-vascular disease

Literature - May 16, 2018 - Verma S, et al. - Circulation 2018
Patients with T2DM and atherosclerotic poly-vascular disease have a higher CV risk than patients with single vascular disease, and in both groups liraglutide consistently reduced major CV outcomes.

Patients with T2DM and atherosclerotic poly-vascular disease have a higher CV risk than patients with single vascular disease, and in both groups liraglutide consistently reduced major CV outcomes.

Clinical trials in diabetes and CVD: What did we learn?

Expert Meeting on CVD & T2DM

10' education - Mar. 22, 2018 - Filippo Crea, Angelyn Bethel, Eduard Montanya
Filippo Crea, Angelyn Bethel and Eduard Montanya discuss the safety and efficacy results of recent trials evaluating GLP-1 RAs and SGLT2 inhibitors, and whether the observed effects represent a class effect or not.

Filippo Crea, Angelyn Bethel and Eduard Montanya discuss the safety and efficacy results of recent trials evaluating GLP-1 RAs and SGLT2 inhibitors, and whether the observed effects represent a class effect or not.

What are the key mechanisms of CV benefit of novel diabetes drugs?

Expert Meeting on CVD & T2DM

10' education - Mar. 22, 2018 - Lina Badimon, Jochen Seufert, Naveed Sattar
Three cardiology and diabetes experts discuss what can be learned from trial results about mechanisms underlying the CV benefits seen with the novel antidiabetic drugs, and which questions remain unanswered.

Three cardiology and diabetes experts discuss what can be learned from trial results about mechanisms underlying the CV benefits seen with the novel antidiabetic drugs, and which questions remain unanswered.

What is the science driving CVD and T2DM?

Expert Meeting on CVD & T2DM

10' education - Mar. 22, 2018 - Wouter Jukema, Stephan Jacob, Ulf Landmesser
Three cardiology and diabetes experts discuss the multifactorial aspect of type 2 diabetes, and the consequential challenges in cardiovascular prevention and management.

Three cardiology and diabetes experts discuss the multifactorial aspect of type 2 diabetes, and the consequential challenges in cardiovascular prevention and management of these patients.

PACE Special: 5 Things a cardiologist should know about diabetes

Download - Download your free copy
Download your free copy

This document covers five topics that help cardiologists understand what is important when treating patients with diabetes, and which risks these patients face. Download your free copy.

Key classes of antidiabetic drugs – How do they work?

5 Things a cardiologist needs to know about diabetes

10' education - Feb. 14, 2018 - Prof Cliff Bailey - Birmingham, UK
Multiple causal pathways contribute to development of T2DM, thus various processes may be targeted to improve glucose regulation. Prof. Bailey briefly summarises the available therapeutic options.

5 Things a cardiologist needs to know about diabetes Multiple causal pathways contribute to development of T2DM, thus various processes may be targeted to improve glucose regulation. Prof. Bailey briefly summarises the available therapeutic options.

GLP-1 receptor agonists reduce CV and all-cause mortality

Literature - Mar. 20, 2018 - Bethel MA, et al. - Lancet Diab Endocrinol 2018

A meta-analysis of available CV outcome trials with GLP-1 receptor agonists shows that they reduce major adverse cardiovascular events in type 2 diabetes patients without significant safety concerns.

Diabetes cardiovascular outcome trials

5 Things a cardiologist needs to know about diabetes

10' education - Feb. 14, 2018 - Prof. Lawrence Leiter, MD - Toronto, ON, Canada
Prof Leiter gives an update of the trials on new antihyperglycemic drugs that have been completed or are ongoing since the FDA mandated demonstration of CV safety. Trials evaluating DPP-4 inhibitors, GLP-1 receptor agonists and SGLT2 inhibitors on CV outcomes are being discussed.

5 Things a cardiologist needs to know about diabetes Prof Leiter gives an update of the trials on new antihyperglycemic drugs (DPP-4 inhibitors, GLP-1 receptor agonists and SGLT2 inhibitors) that have been completed or are ongoing since the FDA mandated demonstration of CV safety.

Oral GLP-1 analogue dose-dependently lowers HbA1c and weight in T2DM patients in phase 3a study

News - Feb. 26, 2018

Data of the PIONEER 1 study show that treatment with the highest tested dose of oral semaglutide in adults with T2DM safely lowered HbA1c by 1.5% at 26 weeks, and yielded a mean 4.1 kg weight loss.

Diabetic patients with chronic kidney disease may benefit more from GLP-1 analogue treatment

10' education - Nov. 15, 2017
Prof. Neil Poulter gives an overview of a subgroup analysis of the LEADER trial in which patients with CKD treated with liraglutide showed a reduction of CV events as compared with those on placebo treatment.

Prof. Neil Poulter gives an overview of a subgroup analysis of the LEADER trial in which patients with CKD treated with liraglutide showed a reduction of CV events as compared with those on placebo treatment.

Diabetes therapies and CVD – Does the ‘how’ matter more than the how much?

10' education - Oct. 27, 2017 - Boston, MA, USA - Dr. Stephen Wiviott - Brigham & Women's Hospital, Boston, USA
Dr. Stephen Wiviott explains how a change in regulatory guidance has dramatically altered the trial landscape and drug development for type 2 diabetes mellitus and has provided substantial information related to CV disease.

Dr. Stephen Wiviott explains how a change in regulatory guidance has dramatically altered the trial landscape and drug development for type 2 diabetes mellitus and has provided substantial information related to CV disease.

GLP-1 receptor agonist approved by FDA for treatment of T2DM

News - Dec. 12, 2017

Based on the results of the SUSTAIN trial, semaglutide is approved by the FDA for the treatment of T2DM patients.

GLP-1 RA & CVD
GLP-1 RA & CVD
GLP-1 RA & CVD
GLP-1 RA & CVD
GLP-1 RA & CVD